Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis

Clinical Pharmacokinetics

Volumn 30, Issue 3, 1996, Pages 194-210

  Bannwarth, Bernard ^a,b   Péhourcq, Fabienne ^a   Schaeverbeke, Thierry ^a   Dehais, Joël ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDEHYDE OXIDASE; ANTIRHEUMATIC AGENT; CHLOROQUINE; COTRIMOXAZOLE; CREATININE; FOLIC ACID; METHOTREXATE; PROBENECID;

CHEMICAL STRUCTURE; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG ANALYSIS; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG OXIDATION; DRUG PROTEIN BINDING; EXTRAVASCULAR SPACE; FOOD INTAKE; GLOMERULUS FILTRATION; HUMAN; IMMUNOASSAY; INTRAMUSCULAR DRUG ADMINISTRATION; JOINT; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY; KIDNEY TUBULE ABSORPTION; LIVER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; SYNOVIAL FLUID;

EID: 0029898079     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630030-00002     Document Type: Review

References (105)

1. Brooks PM. Clinical management of rheumatoid arthritis. Lancet 1993; 341: 286-90
2. Weyand CM, Hicok KC, Conn DL, et al. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992; 117: 801-6
3. Sewell KL, Trentham DE. Pathogenesis of rheumatoid arthritis. Lancet 1993; 341: 283-6
4. Akil M, Amos RS. Rheumatoid arthritis. I: Clinical features and diagnosis. BMJ 1995; 310: 587-90
5. Edmunds JP, Scott DL, Furst DE, et al. New classification of antirheumatic drugs. The evolution of a concept. J Rheumatol 1993; 20: 585-7
6. Bannwarth B, Labat L, Moride Y, et al. Methotrexate in rheumatoid arthritis. An update. Drugs 1994; 47: 25-50
7. Cash JM, Klippel JH. Second line drug therapy for rheumatoid arthritis. N Engl J Med 1994; 330: 1368-75
8. Capell HA, Brzeski M. Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis. Ann Rheum Dis 1992; 51: 424-9
9. Songsiridej N, Furst DE. Methotrexate - the rapidly acting drug. Baillière's Clin Rheumatol 1990; 4: 575-93
10. Wolfe F, Cathey MA. Analysis of methotrexate treatment effect in a longitudinal ohservational study: utility of cluster analysis J Rheumatol 1991; 18: 672-7
11. Kremer JM, Rynes RI, Bartholomew LE. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double blind study. Am J Med 1987; 82: 781-6
12. Ward JR. Earlier intervention with second line therapies. J Rheumatol 1990; 17 Suppl. 25; 18-23
13. Hess EV, Luggen ME. Remodeling the pyramid - a concept whose time has not yet come. J Rheumatol 1989; 16: 1175-6
14. Wilske KR, Healey LA. Remodeling the pyramid - a concept whose time has come. J Rheumatol 1989; 16: 565-7
15. Fries JF. Reevaluationg the therapeutic approach to rheumatoid arthritis: the 'sawtooth' strategy. J Rheumatol 1990; 17 Suppl. 22: 12-5
16. Crom WR, Evans WE. Methotrexate. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principle of drug monitoring. Chap. 29. Vancouver: Applied Pharmacokinetics, 1992; 1-42
17. Bleyer WA. The clinical pharmacology of methotrexate. New applications of an old drug. Cancer 1978; 41: 36-51
18. Sinnett MJ, Groff GD, Raddatz DA, et al. Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1989; 16: 745-8
19. Cosolo W, Drummer OH, Christophidis N. Comparison of high performance liquid chromatography and the Abbott fluorescent polarization radioimmunoassay in the measurement of methotrexate. J Chromatogr 1989; 494: 201-8
20. Beck O, Seideman P, Wennberg M, et al. Trace analysis of methotrexate and 7-hydroxymethotrexate in human plasma and urine by a novel high-performance liquid chromatographic method. Ther Drug Monit 1991; 13: 528-32
21. 10-methylpteroic acid in biological fluids by liquid chromatography with fluorimetric detection. J Chromatogr 1986; 378: 173-81
22. Nuernberg B, Kohlbrenner M, Faulkner R, et al. Rapid quantitation of methotrexate and its metabolites in human serum, urine and bile, using solid-phase extraction and high-performance liquid chromatography. J Chromatogr 1989; 487: 476-82
23. Palm sano F, Cataldi TRI, Zambonin PG. Determination of the ant neoplastic agent methotrexate in body fluids by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1985; 344: 249-58
24. 5-methyltetrahydrofolate, leucovorin, methotrexate and 7-hydroxymethotrexate in biological fluids. J Chromatogr 1984; 488: 379-88
25. Kozloski GD, De Vito JM, Kisicki JC, et al. The effect of food on the absorption of methotrexate sodium tablets in healthy volunteers. Arthritis Rheum 1992; 35: 761-4
26. Oguey D, Kölliker F, Gerber NJ, et al. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 611-4
27. Lebbe C, Beyeler C, Gerber NJ, et al. Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 475-7
28. Skeith KJ, Russell AS, Jamali F, et al. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. J Rheumatol 1990; 17: 1008-10
29. Herman RA, Veng-Pedersen P, Hoffman J, et al. Pharmacokinetics of low dose methotrexate in rheumatoid arthritis patients. J Pharm Sci 1989; 78: 165-71
30. Seideman P, Beck O, Eksborg S, et al. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993; 35: 409-12
31. Zimmerman J. Methotrexate transport in the human intestine. Evidence for heterogeneity. Biochem Pharmacol 1992; 43: 2377-83
32. Ahern M, Booth J, Loxton A, et al. Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs? J Rheumatol 1988; 15: 1356-60
33. Kremer JM, Petrillo GF, Hamilton RA. Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. J Rheumatol 1995; 22: 41-4
34. Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 1978; 3: 1-13
35. Hamilton RA, Kremer JM. The effects of food on methotrexate absorption. J Rheumatol 1995; 22: 630-2
36. Dupuis LL, Koren G, Silverman ED, et al. Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol 1995; 22: 1570-3
37. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845-9
38. Anaya JM, Fabre D, Bressolle F, et al. Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1994; 21: 203-8
39. Combe B, Edno L, Lafforgue P, et al. Total and free methotrexate pharmacokinetics with and without piroxicam in rheumatoid arthritis patients. Br J Rheumatol 1995; 34: 421-8
40. Lafforgue P, Monjanel-Mouterde S, Durand A, et al. Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. J Rheumatol 1993; 20: 263-7
41. Edelman J, Biggs DF, Jamali F, et al. Low-dose methotrexate kinetics in arthritis. Clin Pharmacol Ther 1984; 35: 382-6
42. Brooks PJ, Spruill WJ, Parish RC, et al. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 91-4
43. Auvinet B, Jarrier I, Le Levier F, et al. Biodisponibilité comparée du méthotrexate par voies orale et intramusculaire dans la polyarthrite rhumatoïde. Presse Med 1992; 21: 822
44. Balis FM, Mirro J, Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988; 6: 1882-8
45. Stewart CF, Fleming RA, Arkin CR, et al. Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. Clin Pharmacol Ther 1990; 47: 540-6
46. Tracy TS, Krohn K, Jones DR, et al. The effects of a salicylate. ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992; 42: 121-5
47. Tracy TS, Worster T, Bradley JD, et al. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 1994; 37: 453-6
48. Claudepierre P, Urien S, Chevalier X, et al. Methotrexate serum binding in rheumatoid arthritis. Int J Clin Pharmacol Ther 1994; 32: 113-5
49. Furst DE, Herman RA, Koehnke R, et al. Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci 1990; 79: 782-6
50. Rochas MA, Tufenkji AE, Levillain P, et al. Protein binding of methotrexate to human albumin and serum. A first derivative spectroscopic analysis. Arzneim Forsch 1991; 41: 1286-8
51. Bischoff KB, Dedrick RL, Zaharko DS, et al. Methotrexate pharmacokinetics. J Pharm Sci 1971; 60: 1128-32
52. Bologna C, Edno L, Anaya JM, et al. Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum 1994; 37: 1770-3
53. Stewart CF, Christensen ML, Evens RP, et al. Influence of concomitant aspirin or prednisone on methotrexate synovial fluid concentrations. J Pharm Exp Ther 1987; 243: 131-7
54. Tishler M, Caspi D, Graff E, et al. Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis. Br J Rheumatol 1989; 28: 422-3
55. Wigginton SM, Chu BCF, Weisman MH, et al. Methotrexate pharmacokinetics after intraarticular injection in patients with rheumatoid arthritis. Arthritis Rheum 1980; 23: 119-22
56. Leeb B, Dunky A, Ogris E, et al. Hämatozelluläres Methotrexate bei Langzeittherapie entzündlich rheumatischer Erkrankungen. Acta Med Austriaca 1988; 15: 140-4
57. Kamen BA, Capdevila A. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci USA 1986; 83: 5983-7
58. Slørdal L, Sager G, Aarbakke J. Pharmacokinetic interactions with methotrexate: is 7-hydroxy-methotrexate the culprit? Lancet 1988; i: 591-2
59. Kremer JM, Galivan J, Streckfuss A, et al. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986; 29: 832-5
60. Hendel J, Brodthagen H. Entero-hepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker. Eur J Clin Pharmacol 1984; 26: 103-7
61. Nuernberg B, Koehnke R, Solsky M, et al. Biliary elimination of low-dose methotrexate in humans. Arthritis Rheum 1990; 33: 898-902
62. Seideman P, Albertioni F, Beck O, et al. Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity. Arthritis Rheum 1994; 37: 830-3
63. Hendel J, Nyfors A. Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption. Eur J Clin Pharmacol 1984; 26: 121-4
64. Stewart CK Fleming RA, Germain BF, et al. Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum 1991; 34: 1514-20
65. Sabot C, Debord J, Roullet B, et al. Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics. Int J Clin Pharmacol Ther 1995; 32: 164-9
66. Körber H, Iven H, Gross WL. Bioavailability and pharmacokinetics of methotrexate and its metabolite 7-hydroxy-methotrexate after low dose MTX (25 mg) in patients with chronic rheumatic diseases [abstract]. Arthritis Rheum 1992; 35 Suppl.: S142
67. Janknegt R, Nube MJ, Van Den Hoogenband HM, et al. Pharmacokinetics of methotrexate in continuous ambulatory peritoneal dialysis. Pharm Weekbl Sci 1988; 10: 86-9
68. Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 1995; 22: 38-40
69. Marcé S, Bannwarth B, Schaeverbeke T, et al. Is low dose methotrexate nephrotoxic? J Rheumatol 1993; 20: 1906-7
70. Seideman P, Müller-Suur R. Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis. Ann Rheum Dis 1993; 52: 613-5
71. Bologna C, Anaya JM, Bressolle F, et al. Correlation between methotrexate pharmacokinetic parameters, and clinical and biological status in rheumatoid arthritis patients. Clin Exp Rheumatol 1995; 13: 465-70
72. Albertioni F, Flatø B, Seideman P, et al. Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol 1995; 47: 507-11
73. Ravelli A, Di Fuccia G, Molinaro M, et al. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J Rheumatol 1993; 20: 1573-7
74. Eksborg S, Albertioni F, Beck O, et al. Methotrexate in rheumatoid arthritis - a limited sampling strategy for estimation of the area under the plasma concentration versus time curve. Ther Drug Monit 1994; 16: 560-3
75. Stewart CF, Evans WE. Drug-drug interactions with antirheumatic agents: review of selected clinically important interactions. J Rheumatol 1990; 17 Suppl. 22: 16-23
76. Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother 1992; 26: 234-7
77. Slørdal L, Sager G, Jaeger R, et al. Interactions with the protein binding of 7-hydroxy-methotrexate in human serum in vitro. Biochem Pharmacol 1988; 37: 607-11
78. Kremer JM, Hamilton RA. The effects of nonsteroidal antiinflammatory drugs on methotrexate pharmacokinetics: impairment of renal clearance of methotrexate at weekly maintenance doses but not at 7.5 mg. J Rheumatol 1995; 22: 2072-7
79. Rooney TW, Furst DE, Koehnke R, et al. Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol 1993; 20: 1297-302
80. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19: 1885-94
81. Wallace CA, Smith AL, Sherry DD. Pilot investigation of naproxen/methotrexate interaction in patients with juvenile rheumatoid arthritis. J Rheumatol 1993; 20: 1764-8
82. Dupuis LL, Koren G, Shore A, et al. Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. J Rheumatol 1990; 17: 1469-73
83. Lafforgue P, Monjanel-Monterde S, Durand A, et al. Do steroids influence low dose methotrexate pharmacokinetics. Reply. J Rheumatol 1994; 21: 1171-2
84. Koerber H, Gross WL, Iven H. Do steroids influence low dose methotrexate pharmacokinetics? J Rheumatol 1994; 21: 1170-1
85. Wallace CA, Bleyer WA, Sherry DD, et al. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989; 32: 677-81
86. Fries JF, Singh G, Lenert L, Furst DE. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 1990; 33: 1611-9
87. Rau R, Wassenberg S, Herborn G. Can methotrexate reduce the renal toxicity of parenteral gold? J Rheumatol 1993; 20: 759-61
88. Leeb BF. Should folate supplementation be routinely recommended for older patients receiving methotrexate? Drugs Aging 1994; 5: 319-22
89. Weinblatt ME, Marir AL, Coblyn JS. Low dose leucovorin does no interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. J Rheumatol 1993; 20: 950-2
90. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 833-41
91. Hunt RE, Phillips RM, Shergy WJ. Role of folic acid in limiting methotrexate related side effects [abstract]. Arthritis Rheum 1994; 37 Suppl.: S253
92. He YL, Tanigawara Y, Yasuhara M, et al. Effect of folinic acid on tissue residence and excretion of methotrexate in rats. Drug Metab Dispos 1991; 729-34
93. Banrwarth B, Vernhes JP, Schaeverbeke T, et al. The facts about methotrexate in rheumatoid arthritis. Rev Rhum [Engl Ed] 1995; 62: 499-501
94. Larsen FG, Nielsen-Kudsk F, Jakobsen P, et al. Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. J Clin Pharmacol 1990; 30: 802-7
95. Furst DE, Koehnke R, Burmeister LF, et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989; 16: 313-20
96. Seideman P. Methotrexate - the relationship between dose and clinical effect. Br J Rheumatol 1993; 32: 751-3
97. Mathers D, Russell AS. Methotrexate. In: Dixon JS, Furst DE, editors. Second line agents in the treatment of rheumatic diseases. New York: Marcel Dekker; 1992: 287-310
98. Pons M, Del Blanco J, Filer J, et al. Low-dose methotrexate pharmacokinetics in rheumatoid arthritis: relationship with clinical response [abstract]. Arthritis Rheum 1992: 35 Suppl.: S142
99. Lafforgue P, Monjanel-Mouterde S, Durand A, et al. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1995; 22: 844-9
100. Wallace CA, Sherry DD. A practical approach to avoidance of methotrexate toxicity. J Rheumatol 1995; 22: 1009-12
101. Rheumatoid arthritis clinical trial archive group. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995; 22: 218-23
102. Tishler M, Caspi D, Yaron M. Methotrexate treatment of rheumatoid arthritis: is a fortnightly maintenance schedule enough? Ann Rheum Dis 1992; 51: 1330-1
103. Kremer JM, Davies JMS, Rynes RI, et al. Every-other-week methotrexate in patients with rheumatoid arthritis. A double-blind, placebo-controlled prospective study. Arthritis Rheum 1995; 38: 601-7
104. Hunt PG, Rose CD, Smith C. Parenteral methotrexate effective shelf-life following initial puncture of preservative-protected vial. Arthritis Rheum 1995; 38: 575
105. Tett SE. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet 1993; 25: 392-407